1. Volume 64, Issue 3, Pages 1101-1107 (September 2003)
Transforming growth factor β1 genotype polymorphisms determine AV fistula patency in hemodialysis patients 
Gunnar H. Heine, Christof Ulrich, Urban Sester, Martina Sester, Hans Köhler, Matthias Girndt 
Kidney International 
Volume 64, Issue 3, Pages (September 2003)
DOI: /j x
Copyright © 2003 International Society of Nephrology Terms and Conditions

2. Figure 1
Kaplan-Meier analysis of arteriovenous (AV) fistula patency stratified by transforming growth factor β1 (TGF-β1) producer type. By log-rank test, AV fistula patency was significantly better for TGF-β1 intermediate producers (solid line) compared to TGF-β1 high producers (dotted line); P = TGF-β1 low producers were too low in number to allow a valid statistical comparison to intermediate and high producers.
Kidney International  , DOI: ( /j x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

3. Figure 2
Kaplan-Meier analysis of arteriovenous (AV) fistula patency stratified by age. By log-rank test, AV fistula patency did not differ significantly between patients who were younger than 50years of age (dotted line), 50 to 64years of age (dashed line), and 65years of age and older (solid line), respectively. P = 0.10.
Kidney International  , DOI: ( /j x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

4. Figure 3
Kaplan-Meier analysis of arteriovenous (AV) fistula patency stratified by primary renal disease. By log-rank test, AV fistula patency did not differ significantly between patients with diabetic nephropathy (dotted line) and patients with any other primary renal disease (solid line). P = 0.30.
Kidney International  , DOI: ( /j x)
Copyright © 2003 International Society of Nephrology Terms and Conditions

5. Figure 4
Kaplan-Meier analysis of arteriovenous (AV) fistula patency stratified by comorbidity. By log-rank test, AV fistula patency did not differ significantly between patients with cardiovascular disease (dotted line) and patients without cardiovascular disease (solid line). P = 1.00.
Kidney International  , DOI: ( /j x)
Copyright © 2003 International Society of Nephrology Terms and Conditions